Blood and digital biomarkers in MG

Area of Science:

• Neurology
• Immunology
• Biomarker Discovery

Background:

• Biomarkers are essential for diagnosing and managing myasthenia gravis (MG), a neuromuscular disease.
• Current MG diagnostics rely on antibodies against acetylcholine receptors (AChR) or muscle-specific tyrosine kinase (MuSK).
• Predictive biomarkers for personalized MG treatment are still underdeveloped.

Purpose of the Study:

• To review the current landscape of biomarkers in myasthenia gravis.
• To highlight the potential of emerging biomarkers for diagnosis, prognosis, and treatment selection.
• To explore future directions in MG biomarker research, including multi-omics and digital approaches.

Main Methods:

• Literature review of diagnostic, prognostic, and pharmacodynamic biomarkers in MG.
• Analysis of current and emerging biomarker categories: antibodies, microRNAs, genetic markers, metabolites, cell counts, proteomics, and digital biomarkers.
• Discussion of the role of multi-omics and big data in advancing biomarker discovery.

Main Results:

• Established biomarkers include AChR and MuSK antibodies for diagnosis.
• Prognostic potential shown by microRNAs (e.g., miR-150-5p, miR-30e-5p).
• Pharmacodynamic markers like CD20+ B cells and CYP3A5 gene inform targeted therapies.

Conclusions:

• Biomarkers are critical for optimizing MG diagnosis and treatment.
• Further research into predictive and prognostic biomarkers is needed for personalized MG care.
• Integrating multi-omics and digital technologies holds promise for revolutionizing MG biomarker discovery and patient management.